Quarterly report pursuant to Section 13 or 15(d)

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)

v3.20.2
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)
9 Months Ended
Sep. 30, 2020
Disclosure Text Block Supplement [Abstract]  
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

The following table presents information related to stock options at September 30, 2020:

 

 

Options Outstanding

 

 

Options Exercisable

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

Exercisable

 

 

Exercise

 

 

Number of

 

 

Remaining Life

 

 

Number of

 

 

Price

 

 

Options

 

 

In Years

 

 

Options

 

 

$

2.51-5.00

 

 

 

1,799,216

 

 

 

8.1

 

 

 

1,468,384

 

 

 

5.01-7.50

 

 

 

1,322,407

 

 

 

6.7

 

 

 

926,611

 

 

 

7.51-10.00

 

 

 

323,333

 

 

 

7.3

 

 

 

190,533

 

 

 

10.01-12.50

 

 

 

65,000

 

 

 

9.6

 

 

 

42,083

 

 

 

 

 

 

 

3,509,956

 

 

 

7.5

 

 

 

2,627,631

 

 

 

Options Outstanding

 

 

Options Exercisable

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

Exercisable

 

 

Exercise

 

 

Number of

 

 

Remaining Life

 

 

Number of

 

 

Price

 

 

Options

 

 

In Years

 

 

Options

 

 

$

5.00

 

 

 

1,984,042

 

 

 

7.2

 

 

 

1,900,708

 

 

 

10.00

 

 

 

16,666

 

 

 

0.1

 

 

 

16,666

 

 

 

 

 

 

 

2,000,708

 

 

 

7.2

 

 

 

1,917,374

 

 

Share-based Payment Arrangement, Option, Activity [Table Text Block]

A summary of the stock option activity and related information for the Plan for the nine months ended September 30, 2020 is as follows:

 

                   

Weighted-Average

         
           

Weighted-Average

   

Remaining

   

Aggregate

 
   

Shares

   

Exercise Price

   

Contractual Term

   

Intrinsic Value

 

Outstanding at December 31, 2019

    3,980,804     $ 5.58       6.3     $ 3,130,791  

Grants

    1,015,000       5.59       10.0     $ -  

Exercised

    (1,203,223

)

  $ 5.08                  

Forfeited/expired

    (282,625

)

  $ 5.23                  

Outstanding at September 30, 2020

    3,509,956     $ 5.60       7.53     $ 1,113,941  

Exercisable at September 30, 2020

    2,627,631     $ 5.54       7.07     $ 849,529  

 

                   

Weighted-Average

 
           

Weighted-Average

   

Remaining

 
   

Shares

   

Exercise Price

   

Contractual Term

 

Outstanding at December 31, 2019

    575,000     $ 5.00       9.29  

Grants

    1,599,173     $ 5.31       9.84  

Exercised

    -                  

Forfeited/expired

    (173,465

)

  $ 7.40          

Outstanding at September 30, 2020

    2,000,708     $ 5.04       7.17  

Exercisable at September 30, 2020

    1,917,374     $ 5.04       7.07  

 

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Risk-free interest rate

    0.42% - 1.83

%

Dividend yield

    0

%

Stock price volatility

    86.51% to 92.31

%

Expected life

 

5 – 10 years

 

Weighted average grant date fair value

  $ 4.02  

 

Risk-free interest rate

    0.36% to 0.52

%

Dividend yield

    0

%

Stock price volatility

    125.16% to 126.03

%

Expected life

 

5 – 6 years

 

Weighted average grant date fair value

  $ 4.29  

 

Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block] The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig Technologies, Inc. at September 30, 2020:

 

Exercise

 

 

Number

 

Expiration

 

Price

 

 

Outstanding

 

Date

 

$

3.75

 

 

 

168,468

 

October 2020 to January 2021

 

$

4.38

 

 

 

548,938

 

April 2021

 

$

4.80

 

 

 

125,000

 

February 2025

 

$

6.16

 

 

 

568,910

 

November 2027

 

$

6.85

 

 

 

193,352

 

July 2021 to August 2021

 

 

 

 

 

 

1,604,668

 

 

 

 

Exercise

 

 

Number

 

Expiration

 

Price

 

 

Outstanding

 

Date

 

$

5.00

 

 

 

473,772

 

November 2027

 

 

10.00

 

 

 

6,575

 

May 2025

 

 

 

 

 

 

480,347

 

 

 

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

A summary of the warrant activity for the nine months ended September 30, 2020 is as follows:

 

                   

Weighted-Average

         
           

Weighted-Average

   

Remaining

   

Aggregate

 
   

Shares

   

Exercise Price

   

Contractual Term

   

Intrinsic Value

 

Outstanding at December 31, 2019

    2,744,718     $ 5.40       2.2     $ 3,410,763  

Grants

    125,000       4.80       4.4          

Exercised

    (467,820

)

  $ 3.92                  

Expired

    (797,230

)

  $ 6.44       -       -  

Outstanding at September 30, 2020

    1,604,668     $ 5.27       3.2     $ 519,703  
                                 

Vested and expected to vest at September 30, 2020

    1,604,668     $ 5.27       3.2     $ 519,703  

Exercisable at September 30, 2020

    1,604,668     $ 5.27       3.2     $ 519,703  

 

Nonvested Restricted Stock Shares Activity [Table Text Block]

The following table summarizes the restricted stock activity for the nine months ended September 30, 2020:

 

Restricted shares issued as of December 31, 2019

    262,668  

Granted

    125,000  

Vested and issued

    (219,334

)

Vested restricted shares as of September 30, 2020

    -  

Unvested restricted shares as of September 30, 2020

    168,334  

 

Restricted shares issued as of December 31, 2019

    40,000  

Granted

    1,380,716  

Vested

    -  

Vested restricted shares as of September 30, 2020

    711,786  

Unvested restricted shares as of September 30, 2020

    708,930